Theoretically, bevacizumab can bind to VEGF‐A and interfere with the combination of VEGF‐A and its receptors, blocking the process of tumor angiogenesis and consequently delaying or even inhibiting tumor growth, invasion, metastasis, and other malignant behaviors. The gene discussed is VEGFA; the disease is neoplasm.